On January 5, 2022, Deputy Director Gu Furong of the Songjiang Drug Administration, accompanied by Section Chief Qiu Wenyi and Xiang Jie, conducted an on-site research and guidance visit to ConFlow MedTech, Ltd. Despite adverse weather conditions, the participants in the conference room remained highly engaged and enthusiastic.

At the outset of the meeting, Ms. Chen Xiumin, General Manager of ConFlow MedTech, presented an overview of the company's growth trajectory, team composition, organizational framework, progress in project R&D, as well as advancements in financing to Deputy Director Gu Furong and her colleagues. Deputy Director Gu was informed that, despite being a startup company established just one year ago, ConFlow MedTech has filed for more than 20 international PCT, invention, and utility model patents. She expressed sincere appreciation for ConFlow MedTech's innovative R&D strategy and its robust efforts in safeguarding intellectual property rights. Deputy Director Gu commended ConFlow MedTech for its proactive alignment with the national agenda emphasizing innovation as the primary driver of development and the importance of intellectual property protection as a means to preserve innovation.